Learn More
BACKGROUND GSK1265744 is an HIV integrase strand transfer inhibitor selected for clinical development. OBJECTIVE This first-time-in-human and phase IIa investigation assessed GSK1265744 antiviral activity, pharmacokinetics, safety, and tolerability in healthy and HIV-1-infected subjects. METHODS This double-blind, placebo-controlled study consisted of a(More)
of results 205 subjects received study drug: 86% male, 20% nonwhite, 26%>100,000c/mL HIV-1 RNA, 67% TDF/FTC. Plasma HIV-1 RNA declined rapidly across all S/ GSK1349572 doses with no differences in NRTI subgroups. Three protocol-defined virologic failures occurred, 1 on EFV (<1log10 decline by Week 4), and 2 on S/GSK1349572 (Week 4 and 24 rebound >400c/mL(More)
BACKGROUND The efficacy of dolutegravir (DTG) has been demonstrated in 5 randomized studies in integrase inhibitor (INI)-naive adult populations. To date, a detailed safety review of DTG has not been provided in the literature. OBJECTIVE To describe the safety and tolerability profile of DTG in adults based on 5 randomized, controlled trials and(More)
Background S/GSK1349572(572) showed potent activity in Phase 2 studies in INI-naive HIV-infected subjects and limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. VIKING is an ongoing 24-week Phase 2b pilot study assessing 572 in subjects with RAL-resistant HIV. A good antiviral response during the functional monotherapy phase (through(More)
Although acute high-intensity resistance exercise to exhaustion decreases arterial compliance and increases arterial stiffness, the effect of low-intensity resistance exercise (LRE) to exhaustion on arterial compliance and stiffness remains unknown. The present study investigated the acute effects of LRE on arterial compliance and stiffness. Ten healthy(More)
The purpose of this study was to investigate the acute effect of brisk walking with and without graduated compression stockings (GCSs) on vascular endothelial function and oxidative stress. Ten young healthy subjects walked briskly for 30 min with (GCS trial) and without (CON trial) GCSs in a randomized crossover trial. Brachial artery flow-mediated(More)
Background S/GSK1349572 is a new integrase inhibitor (INI) with in-vitro activity against INI-resistant HIV. Before dosing a large number of subjects in pivotal clinical trials, in-vitro findings were validated in a pilot clinical study (ING112961). At the outset of the study, the degree of susceptibility at which the drug no longer provides benefit was(More)
Background DTG is a once-daily integrase inhibitor that in combination with ABC/3TC, demonstrated superior efficacy with favorable tolerability over TDF/FTC/EFV (SINGLE study) at 48 weeks. EFV is associated with reduced Vitamin D levels through CYP450 enzyme induction; TDF has been associated with decreased bone mineral density (BMD). Antiretroviral(More)
The present study investigated how different training frequencies during menstrual phases affect muscle hypertrophy and strength. Fourteen eumenorrheic women performed 3 sets of arm curls (8-15 repetitions) until failure for 12 weeks. Depending on the menstrual cycle phase, each subject trained each arm separately after either a 3- or a 1-d·wk training(More)
  • 1